Specialized hospital services that aid people with opioid use disorder regardless of why they are admitted can boost the number of patients who begin treatment with FDA-approved medication for opioid ...

Morgan Stanley analyst Michael Cyprys maintained a Hold rating on T Rowe Price (TROW – Research Report) today and set a price target of $97.00.